Hanx Biopharmaceuticals (Wuhan) Co., Ltd. disclosed a share buyback executed on 08 April 2026. The company repurchased 41,400 H-shares on the Hong Kong Stock Exchange at prices ranging from HKD 31.00 to HKD 32.12, translating into a volume-weighted average cost of HKD 31.87 per share and a total consideration of HKD 1.32 million.

Following the transaction, issued shares outstanding (excluding treasury shares) fell by 0.03% to 136.13 million, while treasury shares doubled to 85,000. The total issued share count remained unchanged at 136.22 million because the repurchased shares were retained as treasury stock and not cancelled.

The buyback forms part of a mandate approved on 12 February 2026 that authorises repurchases of up to 13.62 million shares. Cumulative purchases under this mandate now stand at 85,000 shares, representing 0.06% of the company’s issued share base on the mandate date. In accordance with listing rules, Hanx Biopharmaceuticals is subject to a moratorium on new share issues or treasury-share sales until 08 May 2026.